Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (May 2015)
20 slides from Ani Pharmaceuticals's investor presentation, May 15, 2015
Slide 1: Corporate Presentation May 2015
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation May 2015
Slide 2: Forward-Looking Statements
Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statem
Slide 3: ANI Mission Statement
3 ANI Mission Statement ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. ANI’s mission is to develop, manufacture, and market niche generic pharmaceuticals, focusing on opportunities in pai
Slide 4: ANI Overview – Positioned for Growth
ANI Overview – Positioned for Growth ANI Today ▪ Current business – For the quarter ended March 31, 2015: $18.8 million total net revenues □ $12.3 million Generic Rx product revenues +52% y/y □ $4.3 million Brand Rx product revenues +452% y/y □ $2.3 million c ontract manufacturing/services revenues
Slide 5: ANI History and Highlights
5 ANI History and Highlights 2013 Completed merger with BioSante Pharmaceuticals and obtains NASDAQ Global Market listing (NASDAQ: ANIP), June 2013 2013 Announced agreement to acquire 31 previously marketed generic products from Teva for $12.5 million and a percentage of future gross profits, Decemb
Slide 6: Sales and Marketing / Financial Overview
6 Sales and Marketing / Financial Overview
Slide 7: ANI Financial Highlights
ANI Financial Highlights 7 First Quarter 2015 Results ($ in millions) Quarter ended March 31, 2015 March 31, 2014 % Growth Net revenues $18.8 $10.9 72% Adjusted non - GAAP EBITDA (1) $11.5 $ 4.2 170% (1) Please see page 19 for US GAAP reconciliation (2) Please see page 20 for US GAAP reconciliation
Slide 8: ANI Historical Revenue Growth
ANI Historical Revenue Growth 8 $s in millions 39% C ost of sales as a percentage of net revenues, excluding depreciation and amortization 42% 43% 33% 21% 15%
Slide 9: ANI Generic Rx Product Portfolio
ANI Generic Rx Product Portfolio Generic Products Market Share (1) Competitors EE/MT Tablets 49% 2 Fluvoxamine Tablets 55% 2 HC Enema 90% 1 Metoclopramide Solution 29% 2 Opium Tincture 73% 2 Methazolamide Tablets (2) 8% 2 Etodolac Capsules launched March 2015 2 Propafenone Tablets launched March 201
Slide 10: ANI Brand Rx Product Portfolio
ANI Brand Rx Product Portfolio 10 Lithobid ® Tablets Bipolar Disorder Vancocin ® Capsules C. difficile - Associated Diarrhea Cortenema ® U lcerative Colitis Reglan ® Gastroesophageal Reflux 1Q 2015 Net Sales: $4.3M
Slide 11: ANI Contract Manufacturing and Other Current Business
ANI Contract Manufacturing and Other 11 Current Business ▪ Four customers – Eight products and nineteen SKUs – Contract manufacturing and contract packaging ▪ Royalty income from authorized generic of Vancocin ® capsules 1Q 2015 Net Sales: $2.3M
Slide 12: Product Development / Business Development Overview
12 Product Development / Business Development Overview
Slide 13: ANI Product Development Pipeline
13 ANI Product Development Pipeline 47 p roducts in development, total combined current market: $3.3 billion (1) Key Products: – Oral Anti - Cancer: Expedited review granted by FDA; no generics; exclusive API source; once approved potentially only generic player – Lansoprazole ODT: Approved ANDA acq
Slide 14: ANI Business Development Highlights
14 ANI Business Development Highlights Acquired approved NDA for Testosterone gel, May 2015 Acquired approved ANDA for Flecainide tablets, March 2015 Acquired Vancocin ® and related assets, August 2014 Acquired Lithobid ® , July 2014 Acquired 31 generic products, December 2013 Acquired Reglan ® tabl
Slide 15: Manufacturing Overview
a Manufacturing Overview Pormcewias ne
Slide 16: ANI Manufacturing – Main Street Facility
16 ANI Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 square feet of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of labor
Slide 17: ANI Manufacturing – IDC Road Facility
17 ANI Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing and packaging, and warehouse facilities ▪ 100 nano - gram per eight - h
Slide 18: ANI Summary
ANI Summary ANI is an integrated specialty generic pharmaceutical firm with: ▪ Profitable base business generating organic growth – 2015 Annual guidance (1) □ Net revenues of $80 million to $88 million □ Adjusted non - GAAP EBITDA of $48.8 million to $53.1 million □ Adjusted non - GAAP EPS of $2.44
Slide 19: U.S. GAAP Reconciliations
U.S. GAAP Reconciliations 19 2015 2014 Operating Income $9,567 $3,495 Add back Depreciation and amortization 1,327 703 Add back Stock-based compensation 568 47 Adjusted EBITDA $11,462 $4,245 ANI Pharmaceuticals, Inc. and Subsidiary Adjusted non-GAAP EBITDA Calculation and US GAAP to Non-GAAP Reconci
Slide 20: U.S. GAAP Reconciliations
U.S. GAAP Reconciliations 20 2014 2013 Operating Income $20,006 $898 Add back Depreciation and amortization 3,878 1,110 Add back Stock-based compensation 3,423 36 Merger-related expenses, not already added back Adjusted EBITDA $27,307 $7,512 5,468 - ANI Pharmaceuticals, Inc. and Subsidiary Adjusted
ANI Pharmaceuticals — Investor Presentation (May 2015) on 6ix